Remove Cardiomyopathy Remove Heart Disease Remove Preserved Ejection Fraction
article thumbnail

Top 10: Must-reads from the Month of May

DAIC

American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged 3.

article thumbnail

Impact of SGLT2 Inhibitors on the Outcomes of Patients with Cardiac Arrythmias and Transthyretin Cardiac Amyloidosis

HeartRhythm

Transthyretin cardiac amyloidosis (ATTR-CA) is the most common type of amyloid cardiomyopathy which frequently presents with cardiac arrythmias. However, the impact of SGLT2i on cardiovascular outcomes in patients with established cardiac arrythmias and ATTR-CA has not yet been evaluated.

article thumbnail

Vericiguat combined with “new quadruple” therapy enhances cardiac function and life quality in patients with heart failure: a single-center prospective study

Frontiers in Cardiovascular Medicine

Patients diagnosed with reduced ejection fraction (HFrEF) and with heart failure with mildly reduced ejection fraction (HFmrEF) were treated with Vericiguat combined with “ARNI, BB, MRA, SGLT2i” therapy. vs. 43.1 ± 8.5%, P < 0.01), LVEDD (60.5 ± 8.1 vs. 58.2 ± 7.3 mm, mm, P < 0.01), NT-proBNP (4,567.8 ± 5,163.9

article thumbnail

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

DAIC

24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m. 12:15 p.m.

article thumbnail

Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure

Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, rate ratio. The effect of finerenone according to glycaemic status (i.e.

article thumbnail

Ninerafaxstat Well-Tolerated and Safe for Nonobstructive Hypertrophic Cardiomyopathy

DAIC

Ninerafaxstat is designed to help the heart work more efficiently by altering how the muscle uses energy, partially inhibiting the use of fatty acids as fuel and encouraging the use of glucose instead. HCM is the most common genetic heart disease worldwide and is estimated to affect 1 in 500 people.

article thumbnail

Characterizing Heart Failure Across the Spectrum of the Preserved Ejection Fraction: Does Heart Failure With Supranormal Ejection Fraction Exist? Data From the Swedish Heart Failure Registry

Journal of the American Heart Association

The risk of allcause and noncardiovascular mortality and first allcause hospitalization was higher with EF values &gt;55% in crude but not adjusted analyses.ConclusionsAmong patients with HF with preserved EF, 21% had EF 60%.